Cognitive Errors in Clinical Diagnosis:
Gambler’s Fallacy and Posterior Probability Error

Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP

Dr. Fitzgerald covers two related cognitive biases, Gambler’s Fallacy and Posterior Probability Error, which result from rapid, intuitive judgments in the absence of deliberate analysis, and can lead to diagnostic error. Read More

Mnemonics and Memory Aids

Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP

Clinical practice requires a knowledge base of great breadth and depth. Mnemonics and memory aids can be helpful when trying to recall information that requires memorization. In this article, Dr. Fitzgerald has assembled a few mnemonics that may be helpful in your practice and studies. Read More

Poll Shows US Patients Overwhelmingly Support NPs Working to Full Extent of Education

Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP

A recent survey commissioned by the Alliance for Connected Care finds that 82% of patients support allowing NPs to practice to the full extent of their education and clinical training. Read More

ANA Issues Racial Reckoning Statement

The ANA has begun a historic journey of racial reckoning to acknowledge its own past actions that have negatively impacted nurses of color and perpetuated systemic racism. Read More

CDC’s ACIP Panel Backs Enhanced Flu Vaccine for Seniors

The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) unanimously endorsed a group of “enhanced” influenza vaccines believed to provide better protection for older adults. Read More

FDA Approves Dual-Targeted T2D Treatment

The FDA approved tirzepatide (Mounjaro) injection to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. Read More

First Systemic Treatment of Alopecia Areata Approved

The FDA approved baricitinib (Olumiant) oral tablets to treat adult patients with severe alopecia areata, the first approval of a systemic treatment for the condition. Read More

Pneumococcal 15-Valent Conjugate Vaccine Approved for Infants, Children

The FDA approved the use of Merck’s pneumococcal 15-valent conjugate vaccine (Vaxneuvance) to include children 6 weeks through 17 years of age. Read More

FDA Approves Risankizumab-rzaa for Crohn’s Disease Indication

The FDA approved risankizumab-rzaa (Skyrizi), an interleukin-23 antagonist, for the treatment of moderately to severely active Crohn’s disease in adults. Read More

Medication Approved for Uncontrolled Gout

The FDA approved an expanded indication for pegloticase (Krystexxa) injection for intravenous use co-administered with methotrexate to help more people with uncontrolled gout achieve a complete response to therapy. Read More

Nalmefene HCl Injection Available for Reversal of Opioid Drug Effects

Nalmefene HCl injection is now available for the complete or partial reversal of opioid drug effects including respiratory depression induced by natural or synthetic opioids, and in the management of known or suspected opioid overdose. Read More

Oral Treatment for Testosterone Replacement Available

Testosterone undecanoate (TLANDO), an oral treatment for testosterone replacement therapy in adult males, is now available. Read More

COVID-19 News

• FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted

Resource Center

Get more clinical information you can use